An update from Grifols ( (ES:GRF) ) is now available.
Grifols has released its annual report on the remuneration of its directors, highlighting the company’s commitment to aligning its remuneration policy with shareholder interests and long-term sustainability. The report outlines the procedures and principles guiding director remuneration, emphasizing the need for market competitiveness and prudent risk management. The current policy, set to expire in 2025, aims to attract and retain talent while ensuring directors’ independence and adherence to regulatory standards.
More about Grifols
Grifols, S.A. is a global healthcare company based in Barcelona, Spain, primarily operating in the pharmaceutical industry. The company specializes in the production of plasma-derived medicines and other innovative biopharmaceutical products, focusing on enhancing patient care and offering solutions for various medical conditions.
YTD Price Performance: 5.28%
Average Trading Volume: 184,698
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €5.91B
Learn more about GRF stock on TipRanks’ Stock Analysis page.